Study Evaluating LXR-623 in Healthy Japanese Adults

This study has been completed.
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer Identifier:
First received: October 5, 2006
Last updated: August 6, 2009
Last verified: August 2009

The purpose of this study is to evaluate the safety of LXR-623 in healthy Japanese subjects.

Condition Intervention Phase
Drug: LXR-623
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LXR-623 Administered Orally to Healthy Japanese Male Subjects.

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • Safety

Study Start Date: August 2006
Study Completion Date: September 2006
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   20 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy, Japanese Males aged 20-45 years

Exclusion Criteria:

  • A history or active presence of clinically important medical disease
  Contacts and Locations
Please refer to this study by its identifier: NCT00385489

Toshima-ku, Tokyo, Japan, 171-0014
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

No publications provided Identifier: NCT00385489     History of Changes
Other Study ID Numbers: 3201A1-102
Study First Received: October 5, 2006
Last Updated: August 6, 2009
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency processed this record on April 17, 2014